• Our Science

    Programs developing molecules to amplify immune recognition of cancers

  • Clinical Trials

    Targeting various cancers either in monotherapy or in combination

  • Working at iTeos

    Recruiting top talent for both our US and Belgium sites

Pipeline

Program Trial Design Indications Preclinical Phase 1a Phase 1b Phase 2
EOS-448
+ dostarlimab Solid tumors
Monotherapy / + iberdomide Relapsed Refractory Multiple Myeloma
+ pembrolizumab Solid Tumors
Inupadenant
Monotherapy Evaluating Patient and Indication Selection Biomarkers
+ pembrolizumab PD-1 Resistant Melanoma
New Combinations
Inupadenant + EOS-448 Solid Tumors
Inupadenant + EOS-448 + dostarlimab Solid Tumors
EOS-984
Monotherapy IND Enabling Studies
* Studies with solid arrow are dosing patients. Studies with dashed arrows have not yet dosed patients.

Our latest news

  • iTeos Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

    - First patients dosed in clinical trial of anti-TIGIT monoclonal antibody, EOS-448, in combination with pembrolizumab and with inupadenant in patients with solid tumors - Advanced clinical development of inupadenant, EOS-850, an A 2A receptor antagonist, with initiation of an expansion in PD-1

  • iTeos to Report Third Quarter 2021 Financial Results on November 10, 2021

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today

  • iTeos Therapeutics to Participate in Upcoming September Investor Conferences

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immune-oncology therapeutics for patients, today

  • iTeos Reports Second Quarter 2021 Financial Results and Provides Business Update

    Announced co-development and co-commercialization collaboration with GSK for anti-TIGIT monoclonal antibody EOS-448 (GSK’859); $625MM upfront payment in addition to $1.45B in potential milestones, 40/60 cost-sharing of global development, 50/50 profit share in the US, and royalty payments on ex-US

  • iTeos to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 12, 2021

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 05, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today

  • iTeos Therapeutics to Present at Wedbush PacGrow Healthcare Conference 2021

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today

  • iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 08, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today

  • iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations

    EOS-448 is currently in phase I for advanced solid tumours with a randomised PD-1 combination study planned for 2022 iTeos to receive a $625 million upfront payment in addition to potential milestones, and royalty payments on ex-US sales GSK and iTeos will co-commercialise and share profits in the

  • iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of inupadenant, its Adenosine A2A Receptor Antagonist, at ASCO 2021

    Updated results from a dataset of 43 patients showed durable responses and stable disease greater than six months with inupadenant monotherapy in five patients with advanced solid tumors, including previously reported confirmed partial responses in patients with checkpoint-inhibitor resistant